8-K: Zai Lab Reports Strong 2024 Results, Revenue Jumps 50% and Outlines Path to Profitability

Zai Lab announces a 66% increase in fourth-quarter revenue and a 50% increase in full-year revenue, driven by strong product sales and pipeline advancements, with expectations to reach profitability in Q4 2025.

Summary

• Zai Lab Limited announced its financial results for the fourth quarter and full year ended December 31, 2024.
• Total revenues grew 66% year-over-year to $109.1 million for the fourth quarter and 50% year-over-year to $399.0 million for the full year.
• The company anticipates full-year 2025 revenue to be in the range of $560 million to $590 million.
• VYVGART and VYVGART Hytrulo sales reached $30.0 million for the fourth quarter and $93.6 million for the full year.
• Loss from operations decreased 45% year-over-year to $67.9 million for the fourth quarter and 23% year-over-year to $282.1 million for the full year.
• Zai Lab expects to achieve profitability in the fourth quarter of 2025 on a non-GAAP basis.
• The company's cash and cash equivalents, short-term investments, and current restricted cash totaled $879.7 million as of December 31, 2024.
• Zai Lab plans to submit a BLA for bemarituzumab in first-line gastric cancer in the first half of 2025.
• Zai Lab plans to file for regulatory approval in China for Tumor Treating Fields (TTFields) in second-line+ non-small cell lung cancer (NSCLC) and first-line pancreatic cancer in the second half of 2025.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong revenue growth, pipeline advancements, and a clear path to profitability. The strategic collaborations and regulatory milestones further contribute to a favorable sentiment.

Positives

• Significant revenue growth driven by VYVGART, ZEJULA, and NUZYRA.
• Substantial reduction in operating loss, moving towards profitability.
• Strong cash position to fund operations and growth opportunities.
• Advancement of key regional programs, including NDA acceptance of KarXT.
• Positive early clinical data for ZL-1310, a potential first-in-class DLL3 ADC.
• Strategic collaborations with MediLink, Vertex, and Pfizer to expand pipeline and commercial reach.
• NRDL inclusion of AUGTYRO and renewals for NUZYRA and QINLOCK in China.
• FDA granted Orphan Drug Designation to ZL-1310 for the treatment of SCLC.
• Positive topline results from the China subpopulation of the global Phase 3 innovaTV 301 study for Tisotumab Vedotin.

Negatives

• The company is still operating at a loss, although the loss is decreasing.
• Foreign currency losses impacted the net loss.

Risks

• The company's ability to successfully commercialize and generate revenue from approved products.
• The company's ability to obtain funding for its operations and business initiatives.
• The results of clinical and pre-clinical development of product candidates.
• The content and timing of decisions made by regulatory authorities regarding approvals.
• Risks related to doing business in China.

Future Outlook

Zai Lab expects continued rigorous financial discipline and total revenue to be in the range of $560 million to $590 million for full-year 2025 and expects to achieve profitability in the fourth quarter of 2025 on a non-GAAP basis.

Management Comments

• 2024 was a defining year for Zai Lab, marked by strong sales growth, financial strength, and significant pipeline progress.
• 2025 is set to be a transformative year with VYVGART's continued momentum, three new product launches, progress with ZL-1310, and potential regulatory milestones for key assets.
• The VYVGART franchise generated $93.6 million in net product revenue in its exceptional first full year of launch, highlighting the strong demand for innovative therapies in China.
• Zai Lab is stronger than ever, with the infrastructure, innovation, and execution needed to bring medicines to patients around the world and create value for our shareholders.
• Looking ahead, we expect substantial topline growth, targeting $2 billion in revenue by 2028, fueled by the VYVGART franchise for generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP) as well as upcoming potential blockbuster launches, including KarXT for schizophrenia and bemarituzumab for gastric cancer.
• Our innovative pipeline with global rights remains a key focus, with multiple data readouts expected this year and the potential for U.S. Food and Drug Administration (FDA) approval of ZL-1310 as early as 2027.
• We significantly improved our financial position, delivering a substantial reduction in operating loss and advancing towards our goal of achieving profitability in the fourth quarter of 2025.

Industry Context

Zai Lab's focus on innovative therapies in oncology, immunology, neuroscience, and infectious disease aligns with the growing demand for novel treatments in these areas, particularly in China. The company's strategic collaborations and pipeline expansion efforts position it to compete effectively in the biopharmaceutical market.

Comparison to Industry Standards

• Zai Lab's revenue growth of 50% year-over-year is strong compared to the average growth rate of the biopharmaceutical industry.
• The company's focus on China provides a significant market opportunity, as the Chinese pharmaceutical market is one of the fastest-growing in the world.
• The company's pipeline of innovative therapies, including ZL-1310 and KarXT, positions it to compete with larger pharmaceutical companies.
• Zai Lab's strategic collaborations with companies like argenx and Novocure are similar to partnerships pursued by other biopharmaceutical companies to expand their pipelines and market reach.

Stakeholder Impact

• Shareholders will benefit from the company's revenue growth and path to profitability.
• Patients will gain access to innovative therapies for various medical conditions.
• Employees will have opportunities for growth and development within the company.
• The company's success will contribute to the growth of the biopharmaceutical industry in China and worldwide.

Next Steps

• Drive the ramp-up of VYVGART in gMG and VYVGART Hytrulo in gMG and CIDP.
• Maintain ZEJULA leadership position in ovarian cancer in China.
• Prepare for launch of potential blockbuster products including bemarituzumab in gastric cancer and KarXT in schizophrenia.
• Rapidly advance the global Phase 1 study for ZL-1310 (DLL3 ADC with global rights) in SCLC and explore its potential in other neuroendocrine tumors.
• Advance other assets with global rights including ZL-6201 (LRRC15 ADC) and ZL-1503 (IL-13/IL-31R) into Phase 1 development.
• Accelerate the clinical development of efgartigimod (FcRn), povetacicept (APRIL/BAFF), and ZL-1108 (IGF-1R) with several indications in registrational stage.
• Present updated data for ZL-1310 (DLL3 ADC) at a major medical conference in the first half of 2025.
• Initiate a pivotal study for ZL-1310 in 2025.
• Provide data readout for dose escalation of ZL-1310 doublet in combination with atezolizumab and initiate dose escalation for ZL-1310 triplet in combination with atezolizumab and platinum-based chemotherapy.
• Initiate a global Phase 1 study for ZL-1310 in other neuroendocrine tumors in the first half of 2025.
• Provide interim analysis in the global Phase 2 study for ZL-1102 (IL-17 Humabody) in chronic plaque psoriasis in the first half of 2025.
• Provide preclinical data update and initiate a global Phase 1 study for ZL-1503 (IL-13/IL-31R) in moderate-to-severe atopic dermatitis.
• Provide preclinical data update and initiate a global Phase 1 study for ZL-6201 (LRRC15 ADC) in sarcoma.
• Zai Lab partner Amgen to provide data readout from the Phase 3 FORTITUDE-101 study of bemarituzumab combined with chemotherapy versus chemotherapy alone in first-line gastric cancer in the first half of 2025.
• Zai Lab partner Amgen to provide data readout from the Phase 3 FORTITUDE-102 study of bemarituzumab plus chemotherapy and nivolumab versus chemotherapy and nivolumab in first-line gastric cancer in the second half of 2025.
• Zai Lab partner argenx to provide topline results from the Phase 3 ADAPT-SERON study in seronegative gMG.
• Provide topline results from the Phase 2 study in Lupus Nephritis (LN).

Key Dates